Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

VANI

V

Vivani Medical, Inc. (VANI)

NCM – Real vaqt narxi. Valyuta: USD

1.02

-0.06 (-5.56%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

1.03

+0.01 (0.98%)

Bozordan keyin: Mar 27, 2026, 7:16 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for chronic weight management toward a Phase 1 clinical study with results anticipated by the end of 2026.

Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. (“Cortigent”), its wholly-owned subsidiary developing brain implant devices, presented the results of a 6-year Early Feasibility Study of the Orion® Visual Cortical Prosthesis System under development to deliver meaningful visual perception to blind persons at the North American Neuromodulation Society (“NANS”) annual meeting.

Vivani Medical, Inc. Announces Closing of Common Stock Offering

Vivani Medical, Inc. Announces Closing of Common Stock Offering

ALAMEDA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and a concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. Gross proceeds from the two transactions were approximately $4.5 million, before deducting fees and offering expenses.

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

ALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pricing of a best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. The registered offering and the private placement were priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC. The gross proceeds to the Company from the registered offering and private placement are expected to be approximately $4.5 million, before deducting placement agent fees and estimated offering expenses. The registered offering and private placement are expected to close on or about January 27, 2026, subject to the satisfaction of customary closing conditions.

Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results

Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results

Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase 2 dose-ranging study, pending Phase 1 results and regulatory feedback

Vivani Medical, Inc. Announces Closing of Common Stock Offering

Vivani Medical, Inc. Announces Closing of Common Stock Offering

ALAMEDA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 6,000,000 shares of its common stock at an offering price of $1.62 per share and a concurrent private placement of 3,703,703 shares of its common stock at an offering price of $1.62 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. Gross proceeds from the two transactions were approximately $15.7 million, before deducting fees and offering expenses.

Insiders Are Buying These 3 Stocks Hand Over Fist

Insiders Are Buying These 3 Stocks Hand Over Fist

Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company.

Videolar

No Data

There is no data to display

Press-relizlar

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for chronic weight management toward a Phase 1 clinical study with results anticipated by the end of 2026.

Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. (“Cortigent”), its wholly-owned subsidiary developing brain implant devices, presented the results of a 6-year Early Feasibility Study of the Orion® Visual Cortical Prosthesis System under development to deliver meaningful visual perception to blind persons at the North American Neuromodulation Society (“NANS”) annual meeting.

Vivani Medical, Inc. Announces Closing of Common Stock Offering

Vivani Medical, Inc. Announces Closing of Common Stock Offering

ALAMEDA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and a concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. Gross proceeds from the two transactions were approximately $4.5 million, before deducting fees and offering expenses.

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

ALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pricing of a best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. The registered offering and the private placement were priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC. The gross proceeds to the Company from the registered offering and private placement are expected to be approximately $4.5 million, before deducting placement agent fees and estimated offering expenses. The registered offering and private placement are expected to close on or about January 27, 2026, subject to the satisfaction of customary closing conditions.